Kari Hemminki

Laboratory of Translational Cancer Genomics

Head: Kari Hemminki
Prague node

kari.hemminki@lfp.cuni.cz
website of the Institute

HOME INSTITUTION

Faculty of Medicine in Pilsen

RESEARCH PROGRAMME(S)

RP 3 - Biomarkers of cancers and cancer diagnostics

Cancer research – turning mysteries into ways to help; gene by gene, one cell at a time.

COLLABORATION WITH INFRASTRUCTURES

Mission: To discover novel and practical diagnostic, prognostic and predictive cancer markers as well as epidemiologic features allowing for efficient prevention and precisely targeted cancer treatment.
Vision: To know enough about cancer so that patients hearing this diagnosis can be confident in their ability to fight it as well as in our skills to bring them to victory.

The Laboratory of Translational Cancer Genomics deals primarily with the pathophysiology of cancer, mechanisms of interaction with the host tissue, organs and the immune system, metastatic activity and patterns of response to individual (surgical and non-surgical) treatments. In the field of cancer genomics, the aim is to understand the complex relationship between the genetic portraits of cancer cells and their sensitivity/resistance to anticancer drugs and regimens. Long-term objectives include patient-oriented cancer genomics, epithelial mesenchymal transformations, hereditary cancer genomics and epidemiology, including the use of advanced genomics methods in clinical screening and decision-making. Currently, we also focus on targeted therapy based on molecular profiles of tumors.

SELECTED PUBLICATIONS

Hemminki J.; Forsti A.; Hemminki A.; Hemminki K. J.: Survival trends in solid cancers in the Nordic countries through 50 years. Eur J Cancer. 2022 Nov;175:77-85. DOI: 10.1016/j.ejca.2022.08.015
Ajore R.; Niroula A.; Pertesi M.; Cafaro C.; Thodberg M.; Went M.; Bao Erik L; Duran-Lozano L.; Lopez de Lapuente Portilla A.; Olafsdottir T.; Ugidos-Damboriena N.; Magnusson O.; Samur M.; Lareau Caleb A; Halldorsson Gisli H; Thorleifsson G.; Norddahl Gudmundur L; Gunnarsdottir K.; Försti A.; Goldschmidt H.; Hemminki K. J.; van Rhee F.; Kimber S.; Sperling Adam S; Kaiser M.; Anderson K.; Jonsdottir I.; Munshi N.; Rafnar T.; Waage A.; Nilsson B.: Functional dissection of inherited non-coding variation influencing multiple myeloma risk. Nat Commun. 2022 Jan 10;13(1):151. DOI: 10.1038/s41467-021-27666-x
Tichánek F.; Foersti A.; Hemminki A.; Hemminki O.; Hemminki K. J.: Survival in melanoma in the nordic countries into the era of targeted and immunological therapies. Eur J Cancer. 2023 Jun:186:133-141. DOI: 10.1016/j.ejca.2023.03.019
Kraemer A.; Bochtler T.; Pauli C.; Baciarello G.; Delorme S.; Hemminki K. J.; Mileshkin L.; Moch H.; Oien K.; Olivier T.; Patrikidou A.; Wasan H.; Zarkavelis G.; Pentheroudakis G.; Fizazi K.: Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Mar;34(3):228-246. DOI: 10.1016/j.annonc.2022.11.013
Hemminki K. J.; Hemminki J.; Foersti A.; Sud A.: Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment. Leukemia. 2023 Apr;37(4):854-863. DOI: 10.1038/s41375-023-01852-w